摘要
目的探讨奥卡西平与碳酸锂治疗躁狂发作的疗效与安全性。方法躁狂发作患者70例,随机分为奥卡西平组34例,碳酸锂组36例。奥卡西平组给予奥卡西平0.6～1.8 g.d-1,碳酸锂组给予碳酸锂0.5～1.5 g.d-1。两组均联合给予非典型抗精神病药物治疗,应用Beck-Rafaelsen躁狂评定量表(BRMS)观察6周。结果两组治疗后BRMS评分均明显下降(均P<0.01)。奥卡西平组治疗第1周末、第2周末的BRMS评分均显著低于碳酸锂组(均P<0.05),减分率显著高于碳酸锂组(P<0.05),临床有效率显著高于碳酸锂组(P<0.05)。两组不良反应相似(P>0.05)。结论奥卡西平联合非典型抗精神病药物控制躁狂发作的疗效优于碳酸锂,安全性良好。
Objective To assess the efficacy and safety of oxcarbazepine and lithium carbonate for treating manic episode. Methods 70 patients with manic episode were randomly divided into oxcarbazepine group（n=34） and lithium carbonate group（n=36）.The patients in oxcarbazepine group were treated with 0.6-1.8 g·d-1 oxcarbazepine,and those in lithium carbonate group were treated with 0.5-1.5 g·d-1 lithium carbonate,on the base of atypical antipsychotics therapy.All patients were assessed by Beck-Rafaelsen manic scale（BRMS） for 6 weeks. Results BRMS in two groups significantly decreased after treatment for 6 weeks（P0.01）.BRMS of oxcarbazepine group was significantly lower than that of lithium carbonate group at the end of 1st and 2nd week after treatment（P0.05）.The efficacy rate of oxcarbazepine group and full remission rate after treatment were significantly higher than those in the lithium carbonate group（P0.05）.Similar side effects was found between two groups（P0.05）. Conclusion Combination of oxcarbazepine and atypical antipsychotics are more effective than lithium carbonate and safe.
出处
《医药导报》
CAS
2011年第3期317-319,共3页
Herald of Medicine
关键词
奥卡西平
碳酸锂
躁狂发作
Oxcarbazepine
Lithium carbonate
Manic episode
